Related Experiment Video
Updated: Jan 8, 2026
Therapeutic Evaluation of Fecal Microbiota Transplantation in an Interleukin 10-Deficient Mouse Model
Published on: April 6, 2022
Gut Microbiome and Paediatric Inflammatory Bowel Disease: Emerging Mechanistic and Therapeutic Insights Into
1Department of Pediatric Gastroenterology, Chengdu Women's and Children's Central Hospital, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China.
Insights
The gut microbiome is vital for children's gut health and inflammatory bowel disease (IBD) treatment. Research shows that gut bacteria imbalances (dysbiosis) contribute to paediatric IBD, with new therapies targeting these microbes.
Area of Science:
- Gastroenterology
- Microbiology
- Immunology
Background:
- The gut microbiome plays a critical role in pediatric intestinal development and immune system maturation.
- Imbalances in gut microbial communities (dysbiosis) are increasingly linked to the development of pediatric inflammatory bowel disease (IBD).
Purpose of the Study:
- To review the relationship between gut microbiome dysbiosis and the pathogenesis of pediatric IBD.
- To explore emerging therapeutic strategies for pediatric IBD that target the gut microbiome.
Main Methods:
- Literature review of studies investigating the gut microbiome in pediatric IBD.
- Analysis of microbial metabolites, barrier function, and immune responses in relation to IBD.
- Examination of current and emerging microbiome-based therapies.
Main Results:
- Gut dysbiosis contributes to pediatric IBD through altered microbial metabolites, compromised gut barrier integrity, and aberrant immune activation.
- Specific microbial signatures in children with IBD correlate with disease presentation and treatment outcomes, indicating potential biomarker utility.
- Emerging therapies like targeted nutrition, microbial consortia, and fecal microbiota transplantation show promise for managing pediatric IBD.
Conclusions:
- Restoring microbial balance in the gut offers a potential avenue for more sustainable and less toxic management of pediatric IBD.
- Further large-scale, longitudinal studies are needed to develop and validate pediatric-specific microbiome-based interventions.
- Addressing challenges like small cohort sizes and data variability is crucial for advancing microbiome therapies in pediatric IBD.
Abstract:
The gut microbiome is crucial for paediatric intestinal development and holds therapeutic potential for inflammatory bowel disease (IBD). This review explores the link between gut microbiome dysbiosis and paediatric IBD pathogenesis. Microbial colonisation during early developmental windows establishes immune tolerance, reinforces epithelial barrier integrity and regulates metabolic functions. Dysbiosis contributes to disease through reduced beneficial microbial metabolites, impaired mucosal barriers and aberrant immune activation. Distinct dysbiosis signatures in paediatric patients correlate with clinical phenotypes and treatment responses, suggesting potential biomarkers. Emerging therapies include targeted nutritional therapies, designed microbial consortia, microbiota transplantation and tailored diets. By correcting underlying microbial imbalances, these approaches may offer more sustainable disease control with fewer side effects than conventional anti-inflammatory treatments. However, challenges persist, such as limited paediatric cohort sizes, a lack of causal mechanistic data and variability in microbiome profiles due to diet, geography and developmental stage. Future research requires larger longitudinal studies to develop paediatric-specific interventions that restore microbial equilibrium, ultimately transforming IBD management in children.
More Related Videos
08:24Injections of Lipopolysaccharide into Mice to Mimic Entrance of Microbial-derived Products After Intestinal Barrier Breach
Published on: May 2, 2018
09:44Evaluating Therapeutic Interventions in the SHIP-deficient Mouse Model of Crohn Disease-like Ileitis and Fibrosis
Published on: October 14, 2025
Related Concept Videos
01:29Inflammatory Bowel Disease IV: Pharmacological Management
Pharmacologic...
01:30Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
01:17Irritable Bowel Syndrome I: Introduction
IBS is a chronic condition that can persist over a long period or recur frequently.
The pathogenesis of IBS involves a complex interplay of the following factors:
Altered...
01:29Microorganisms in Medicine and Therapeutics
01:27Inflammatory Bowel Disease I: Ulcerative Colitis
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
01:30Inflammatory Bowel Disease II: Crohn's Disease
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by...